Arrowhead Pharmaceuticals Inc. (ARWR)
NASDAQ: ARWR · Pharmaceutical Preparations · Pasadena, CA
Our rating: Neutral
Call changed from Cautious to Neutral at $47.78, moderate conviction, November 13, 2026.
Breaks if: Turn Positive if Arrowhead reports at least $200M in revenue in any single quarter over the next four quarters without a disclosed one-time payment, implying a sustainable royalty or milestone cadence is developing. Turn Cautious if trailing free cash flow turns negative for two consecutive quarters and revenue normalizes below $80M on an annualized basis, signaling the licensing windfall has cleared without a durable replacement taking its place.
Key figures
| Market value | $5.8B |
|---|---|
| Revenue, last 12 months | $451M |
| Net income, last 12 months | −$724M |
| Free cash flow, last 12 months | −$284M |
| Price to earnings | n/a |
| Free cash flow yield | −4.9% |
| Dividend yield | 0.0% |
| Operating margin | −156.9% |
| Return on equity | −280.5% |
| Beta to the S&P 500 | 1.54 |
| Volatility, annualized | 64.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $38M | −85.3% | $-3.01 | −$196M |
| June 30, 2026 | $75M | 171.0% | $-1.36 | −$181M |
| March 31, 2026 | $74M | −86.4% | $-0.93 | $82M |
| December 31, 2025 | $264M | 10461.3% | $0.22 | $11M |
| September 30, 2025 | $256M | n/a | $-0.18 | $13M |
| June 30, 2025 | $28M | n/a | $-1.26 | −$157M |
| March 31, 2025 | $543M | n/a | $2.75 | $455M |
| December 31, 2024 | $3M | −29.6% | $-1.39 | −$154M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $7.17B: Claude 2%, Gemini 1%, Mistral 2%
- Diluted earnings per share are at least $0.22: Claude 20%, Gemini 15%, Mistral 15%
- Free cash flow for the quarter is at least $0.01B: Claude 18%, Gemini 20%, Mistral 30%
27 ledger entries and 72 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.